-
公开(公告)号：US09022977B2
公开(公告)日：2015-05-05
申请号：US13915516
申请日：2013-06-11
Applicant: BioCardia, Inc.
Inventor： Daniel C. Rosenman , Daniel Kayser , Michael Keleher , Nick Fravala , Richard Cook , Mark Tale , Frank Arko , Simon Stertzer , Peter A. Altman
CPC classification number: A61M25/0113 , A61B17/0057 , A61F2/2427 , A61M25/0045 , A61M25/005 , A61M25/0051 , A61M25/0052 , A61M25/01 , A61M25/0136 , A61M25/0138 , A61M25/0141 , A61M25/0147 , A61M25/0152 , A61M2025/0687 , A61M2025/09133 , A61M2210/12
Abstract: Methods for easy, atraumatic access to areas of the vasculature that are otherwise difficult to access, using steerable guide catheters constructed with components that are selected to provide optimal navigability, torque transfer, and push ability for a variety of typical percutaneous access routes. The catheter wall thickness in the deflecting segment of the guide catheter is about 1 French (⅓ mm) or less, and includes a slotted deflection tube, and this construction allows a very tight turning radius which in turn enables guide catheter access to regions of the vasculature that are otherwise inaccessible.
Abstract translation: 使用由可选择的导向导管构成的导向导管，用于容易地，无创地进入否则难以进入的脉管系统区域的方法，以提供针对各种典型经皮通路的优化导航性，扭矩传递和推动能力。 引导导管的偏转段中的导管壁厚度约为1英寸（1/3毫米）或更小，并且包括开槽偏转管，并且该结构允许非常紧密的转动半径，这进而使引导导管进入 否则无法进入的脉管系统。
-
公开(公告)号：US20130274714A1
公开(公告)日：2013-10-17
申请号：US13915516
申请日：2013-06-11
Applicant: BioCardia, Inc.
Inventor： Daniel C. Rosenman , Daniel Kayser , Michael Keleher , Nick Fravala , Richard Cook , Mark Tale , Frank Arko , Simon Stertzer , Peter A. Altman
IPC: A61M25/01
CPC classification number: A61M25/0113 , A61B17/0057 , A61F2/2427 , A61M25/0045 , A61M25/005 , A61M25/0051 , A61M25/0052 , A61M25/01 , A61M25/0136 , A61M25/0138 , A61M25/0141 , A61M25/0147 , A61M25/0152 , A61M2025/0687 , A61M2025/09133 , A61M2210/12
Abstract: Methods for easy, atraumatic access to areas of the vasculature that are otherwise difficult to access, using steerable guide catheters constructed with components that are selected to provide optimal navigability, torque transfer, and push ability for a variety of typical percutaneous access routes. The catheter wall thickness in the deflecting segment of the guide catheter is about 1 French (⅓ mm) or less, and includes a slotted deflection tube, and this construction allows a very tight turning radius which in turn enables guide catheter access to regions of the vasculature that are otherwise inaccessible.
Abstract translation: 使用由可选择的导向导管构成的导向导管，用于容易地，无创地进入否则难以进入的脉管系统区域的方法，以提供针对各种典型经皮通路的优化导航性，扭矩传递和推动能力。 引导导管的偏转部分中的导管壁厚度约为1法国（1/3毫米）或更小，并且包括开槽的偏转管，并且该结构允许非常紧的转动半径，这进而使引导导管进入区域 的血管系统，否则无法进入。
-
公开(公告)号：US6443949B2
公开(公告)日：2002-09-03
申请号：US17776598
申请日：1998-10-23
Applicant: BIOCARDIA INC
Inventor： ALTMAN PETER A
CPC classification number: A61N1/0575 , A61B18/1492 , A61B2017/00247 , A61B2018/00011 , A61B2018/00351 , A61B2018/00392 , A61B2018/00577 , A61B2018/00839 , A61B2018/1425 , A61B2018/1435 , A61B2218/002 , A61K9/127 , A61K9/1676 , A61K9/50 , A61K9/5084 , A61M2025/0089 , Y10S977/775 , Y10S977/907
Abstract: A method of treating the heart and other body tissues by injecting a compound comprised of microsphere encapsulated macromolecule therapeutic agents into the myocardium, such that the microsphere size inhibits capillary transport of the compound but may permit lymphatic transport of the compound, and the compound releases therapeutic agents upon degradation of the microsphere.
Abstract translation: 通过将由微球包封的大分子治疗剂组成的化合物注射到心肌来治疗心脏和其他身体组织的方法，使得微球体尺寸抑制化合物的毛细管转运，但可允许化合物的淋巴转运，并且化合物释放治疗 试剂在微球降解后。
-
公开(公告)号：US11642377B2
公开(公告)日：2023-05-09
申请号：US16583721
申请日：2019-09-26
Applicant: BioCardia, Inc.
Inventor： Ian McNiece , Peter Altman
IPC: A61K35/28 , A61P9/10 , C12N5/0775 , C12N5/077
CPC classification number: A61K35/28 , A61P9/10 , C12N5/0657 , C12N5/0663 , C12N2502/1394
Abstract: The present disclosure provides use of neurokinin 1 receptor (NK1R) as a marker for identifying and/or isolating multipotential cells. The present disclosure provides cell populations enriched by methods of the present disclosure and therapeutic uses of these cells and agents derived from these cells.
-
公开(公告)号：US20190151614A1
公开(公告)日：2019-05-23
申请号：US16113556
申请日：2018-08-27
Applicant: BioCardia, Inc.
Inventor： Wai Hsueh , Ken Vien , James B. Ross
IPC: A61M25/01
Abstract: A bi-directional steerable catheter adapted for delivery into a patient's vasculature. The pull wires which are used to tension the deflectable segment of the steerable catheter are wound in parallel around the axis of the steerable catheter on opposite sides of the steerable catheter.
-
Patent Agency Ranking
36.发明申请公开(公告)号：US20180321240A1
公开(公告)日：2018-11-08
申请号：US15910610
申请日：2018-03-02
Applicant: BioCardia, Inc.
Inventor： Peter ALTMAN , Cheryl WONG PO FOO
IPC: G01N33/569 , A61K35/28
CPC classification number: G01N33/56966 , A61K35/28 , G01N2333/70596 , G01N2800/52
Abstract: Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
-
37.发明申请公开(公告)号：US20170363623A1
公开(公告)日：2017-12-21
申请号：US15693679
申请日：2017-09-01
Applicant: BioCardia, Inc.
Inventor： Peter Altman , Cheryl Wong Po Foo
IPC: G01N33/569 , A61K35/28
CPC classification number: G01N33/56966 , A61K35/28 , G01N2333/70596 , G01N2800/52
Abstract: Autologous bone marrow cells (BMC) are transplanted to a heterologous site in a patient after a sample of the patient's BMC has been tested and found to have a phenotypic profile which meets minimum criteria for transplantation. The phenotypic profile may be obtained by screening a sample of bone marrow cells (BMC) from the patient for the phenotypic profile, such as a CD profile, the phenotype profile may be assessed to determine the likelihood that the BMC will be suitable for transplantation to the heterologous tissue site without enriching particular phenotypic population(s) of the BMC.
-
公开(公告)号：US20170327790A1
公开(公告)日：2017-11-16
申请号：US15664988
申请日：2017-07-31
Applicant: BioCardia, Inc.
Inventor： Didier Rouy , Peter A. Atlman , Benjamin Koziner
CPC classification number: C12N5/0663 , A61K9/0019 , A61K35/00 , A61K35/10 , A61K35/28 , A61K2035/124 , C12N2500/84 , C12N2502/11 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
Abstract: A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.
-
公开(公告)号：US09752123B2
公开(公告)日：2017-09-05
申请号：US15055418
申请日：2016-02-26
Applicant: BioCardia, Inc.
Inventor： Didier Rouy , Peter A. Atlman , Benjamin Koziner
CPC classification number: C12N5/0663 , A61K9/0019 , A61K35/00 , A61K35/10 , A61K35/28 , A61K2035/124 , C12N2500/84 , C12N2502/11 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
Abstract: A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium which can be used in a clinical setting, and a business method for performing such expansions in the future as a service for patients. A method for expanding mesenchymal cells derived from autologous bone marrow in autologous culture medium including a diagnostic kit for the autologous cell therapy to determine whether a patient will respond to the autologous cell therapy for treatment of a disease, in which said kit comprising a system for detecting gene and protein expression comprising at least two isolated DNA molecules wherein each isolated DNA molecule detects expression of a gene that is differentially expressed in the tissue of the patient that is intended to be the source of the autologous cell therapy.
-
公开(公告)号：US09517199B2
公开(公告)日：2016-12-13
申请号：US14630305
申请日：2015-02-24
Applicant: BioCardia, Inc.
Inventor： Luis M. de la Fuente , Simon H. Stertzer , Julio Argentieri , Eduardo Penaloza , Peter A. Altman
CPC classification number: A61K9/0019 , A61K35/14 , A61K35/28 , A61K35/32 , A61K35/35
Abstract: A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).
Abstract translation: 一种治疗慢性心肌梗塞的方法，包括在慢性心肌梗死（MI）患者中，在低或运动不全的区域周围的自体骨髓（ABM）单核细胞的螺旋针经心内传递。 治疗是安全的并且改善射血分数（EF）。
-
-
-
-
-
-
-
-
-
Search Results
63
records
(took 0.021 seconds)
